Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLC-2716 in Hypertriglyceridemia and NAFLD
NCT06564584Phase 2Recruiting
- Sponsor
- OrsoBio
- Start
- Aug 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TLC-2716 in hypertriglyceridemia, non-alcoholic fatty liver disease (NAFLD), sponsored by OrsoBio. Started Aug 2024; status: recruiting.
02
Drugs
TLC-2716
03
Conditions
hypertriglyceridemianon-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT06564584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06564584.